Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 2

Status

Completed 4Recruiting 3Terminated 1

Sponsor Class

INDUSTRY 11OTHER 8NETWORK 2

Study Type

Interventional 8

Sponsor

Cancer Type

Gastrointestinal 142Sarcoma 22Tumor-Agnostic 8CNS 7Thoracic 5Gynecologic 5Other solid neoplasm 4Other hematologic neoplasm 4Genitourinary 4Dermatologic 4Plasma cell 2Myeloid 2Lymphoid 2Head & Neck 2Endocrine 2Breast 2NET 1Classical hematology 1

Conditions

Neoplasm Metastasis 4Neoplasms 2Adenocarcinoma 2

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
OTHER × regorafenib × Tumor-Agnostic × Clear all
NCT07567222 2026-05-06

Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors

West China Hospital

Phase 1 Recruiting
54 enrolled
Tumor-Agnostic

Neoplasms

NCT04116541 2026-04-24

MegaMOST

Centre Leon Berard

Phase 2 Recruiting
455 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03406871 2025-01-24

REGONIVO

National Cancer Center Hospital East

Phase 1 Completed
50 enrolled 14 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT03722108 2023-10-16

REGIRI

UNICANCER

Phase 1/2 Terminated
89 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02095054 2021-04-01

Regorafenib and Cetuximab in Patients With Advanced Malignancy

M.D. Anderson Cancer Center

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01896856 2020-10-06

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
118 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01929616 2019-06-25

RegARd-C

Jules Bordet Institute

Phase 2 Completed
141 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡